Please upgrade your browser.
Effective July 1, 2017, as part of the settlement the companies entered into an amendment (the “Amendment”) to the existing Collaboration Agreement, dated December 22, 2006, to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016, and aligns both companies’ interests in advancing cobimetinib as a promising therapy for patients with multiple forms of cancer.
Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the kidney.
"To make progress we need to look at investing more money to hasten the implementation of the Cancer Strategy; we need to speed up, not slow down, patient access to cost-effective medicines in the NHS and we need to create a more ambitious plan for using real-world evidence to shine a light on cancer treatment outcomes."
A donation to support the work of young investigators is made for each quiz taken. There is a ten-question quiz and a one-question quiz. Each takes less than a minute to complete. See how you compare to others!
A drug which could prolong life for people with advanced kidney cancer has been approved for use on the NHS in England and Wales.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of FOTIVDA® (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC). EUSA's marketing authorisation application included data from the TiVO-1 pivotal study, which included over 500 patients with advanced RCC.
Take a one-question (or a 10-question) quiz and a donation to support kidney cancer research will be made by an anonymous donor. It costs you nothing and could help to save lives. World Kidney Cancer Remembrance Day is June 21, 2017.
We invite you to upload photos of your loved ones, including those who have survived renal cancers, family and friends, and those who whose memory we honor on June 21, 2017, in a worldwide celebration of life and remembrance.
Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.
The Kidney Cancer Association announces another Young Investigator Award (YIA) made collaboratively with Conquer Cancer Foundation (ASCO). The Award is a research grant that supports promising investigators and encourages quality research in clinical oncology, providing funding during a physician’s pivotal career transition from a fellowship program to a faculty appointment.
|Powered by NeonCRM|